Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management
Zealand Pharma Company announcement – No. 11 / 2026 Zealand Pharma and Roche to advance petrelintide, an amylin…
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
F. Hoffmann-La Roche Ltd Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7%…
Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal
Roche RHHBY has announced that the mid-stage study ZUPREME-1, evaluating the investigational candidate petrelintide for the treatment of…
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
F. Hoffmann-La Roche Ltd Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7%…
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
F. Hoffmann-La Roche Ltd Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7%…
Roche’s CT-388 Obesity Data Tests New Growth Pillar Potential
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply…